ORCHID PHARMA LIMITED (ORCHPHARMA) financials

ORCHID PHARMA LIMITED (ORCHPHARMA) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.[1]

Market Cap: ₹5,457Cr.
Current Price: ₹911
Stock P/E: 113
ROE: 2.98%
ROCE: 3.28%
Book Value: ₹316
Dividend Yield: 0.00%
52W High / Low: ₹1,144/471

In Jun 2026, ORCHID PHARMA LIMITED (ORCHPHARMA) reported sales ₹304 Cr and net profit ₹12 Cr.

Annual TTM: sales ₹1,073 Cr, net profit ₹41 Cr.

Shareholding: Promoters 74.45% (Sep 2026), FIIs 0.93% (Sep 2026), DIIs 17.44% (Sep 2026), Public 7.17% (Sep 2026), No. of Shareholders 33,790% (Sep 2026).

ORCHPHARMA quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	223	217	237	263	194	207	368	304
Expenses	193	191	203	269	194	204	336	289
Operating Profit	30	26	34	-6	-1	3	32	15
OPM %	13%	12%	14%	-2.1%	-0.3%	1.4%	9%	4.9%
Other Income	8	10	6	16	15	3	14	10
Interest	3	4	4	2	4	3	2	2
Depreciation	9	9	9	11	9	9	11	11
Profit before tax	26	24	28	-2	2	-6	33	12
Tax %	0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	26	24	28	-2	2	-6	33	12
EPS in Rs	5.05	4.71	5.49	-0.48	0.44	-1.15	6.44	2.35
Raw PDF	—	—	—	—	—	—	—	—

ORCHPHARMA profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	481	451	557	666	819	1,398	1,233	1,073
Expenses	470	392	498	581	708	1,241	1,181	1,024
Operating Profit	11	59	59	84	111	157	52	49
OPM %	2.4%	13%	11%	13%	14%	11%	4.2%	4.6%
Other Income	-37	-15	57	57	30	31	35	42
Interest	6	52	33	33	17	13	9	11
Depreciation	118	109	87	55	33	42	43	40
Profit before tax	-150	-117	-5	54	92	132	35	41
Tax %	0%	0%	0%	0%	-4%	-7%	0%	—
Net Profit	-150	-117	-5	54	95	142	35	41
EPS in Rs	-36.71	-28.70	-1.18	13.28	18.68	27.98	6.83	8.08
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	—

ORCHPHARMA balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	89	41	41	41	41	51	15	15
Reserves	-844	757	641	637	691	1,168	1,551	1,587
Borrowings	3,230	566	453	268	331	135	154	129
Other Liabilities	518	86	90	148	160	199	366	367
Total Liabilities	2,993	1,450	1,224	1,094	1,223	1,552	2,086	2,098
Fixed Assets	1,161	858	670	584	573	616	688	671
CWIP	278	26	7	10	46	24	44	168
Investments	0	0	15	49	50	69	80	88
Other Assets	1,553	566	531	452	554	842	1,274	1,171
Total Assets	2,993	1,450	1,224	1,094	1,223	1,552	2,086	2,098

ORCHPHARMA cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	15	80	24	90	13	131	64	142
Cash from Investing Activity	45	167	67	113	-27	-316	-51	-116
Cash from Financing Activity	-0	-250	-165	-217	31	167	3	-41
Net Cash Flow	60	-3	-73	-14	18	-18	15	-15
Free Cash Flow	9	76	24	235	-13	76	-8	-20
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	-308%	615%	33%	156%	16%	117%	50%	270%

ORCHPHARMA shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	74.45%
FIIs	2.53%	2.69%	1.39%	1.56%	1.17%	0.87%	0.80%	0.93%
DIIs	19.00%	20.10%	19.43%	19.04%	19.38%	20.24%	20.75%	17.44%
Public	8.63%	7.37%	9.34%	9.57%	9.61%	9.04%	8.62%	7.17%
No. of Shareholders	34,158	34,303	39,827	38,155	35,709	35,118	33,433	33,790

ORCHPHARMA key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	88	50	107	105	116	84	92	113
Inventory Days	219	257	240	201	217	199	187	161
Days Payable	354	110	109	140	130	135	116	119
Cash Conversion Cycle	-47	197	237	165	204	148	163	154
Working Capital Days	-1,159	197	330	121	79	140	112	124
ROCE %	-5%	-4%	-4%	-2%	5%	9%	10%	3%

ORCHPHARMAUpdated 18 Oct 2026, 10:26

Orchid Pharma Limited

ORCHPHARMAUpdated 18 Oct 2026, 10:26

Market Cap

₹5,457Cr.

Current Price

₹911

High / Low

₹1,144/471

Stock P/E

113

ROE2.98%

ROCE3.28%

Book Value₹316

Face Value₹10.0

Dividend Yield0.00%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	183	6	161	2	8	11	0	11	2.13
Sep 2023	199	4	175	8	8	20	0	20	3.99
Dec 2023	221	4	185	7	9	31	0	31	6.02
Mar 2024	217	3	188	13	8	30	-11	33	6.54
Jun 2024	244	3	211	8	8	29	0	29	5.74
Sep 2024	223	3	193	8	9	26	0	26	5.05
Dec 2024	217	4	191	10	9	24	0	24	4.71
Mar 2025	237	4	203	6	9	28	0	28	5.49
Jun 2025	263	2	269	16	11	-2	0	-2	-0.48
Sep 2025	194	4	194	15	9	2	0	2	0.44
Dec 2025	207	3	204	3	9	-6	0	-6	-1.15
Mar 2026	368	2	336	14	11	33	0	33	6.44
Jun 2026	304	2	289	10	11	12	0	12	2.35

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015 18m	1736	537	1416	156	321	-383	-50	-191	-22.41
Mar 2016	879	294	705	-28	143	-292	-6	-274	-30.83
Mar 2017	755	347	740	-59	146	-537	-9	-489	-54.91
Mar 2018	644	310	622	20	133	-401	-12	-355	-39.94
Mar 2019	584	7	590	42	130	-101	0	-101	-11.36
Mar 2020	481	6	470	-37	118	-150	0	-150	-36.71
Mar 2021	451	52	392	-15	109	-117	0	-117	-28.7
Mar 2022	557	33	498	57	87	-5	0	-5	-1.18
Mar 2023	666	33	581	57	55	54	0	54	13.28
Mar 2024	819	17	708	30	33	92	-4	95	18.68
Mar 2025	1398	13	1241	31	42	132	-7	142	27.98
Mar 2026	1233	9	1181	35	43	35	0	35	6.83
TTM	1073	11	1024	42	40	41	—	41	8.08

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	74.45%
FIIs	0.93%
DIIs	17.44%
Public	7.17%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Dec 2023	69.84%	4.14%	14.51%	—	11.52%
Mar 2024	69.84%	1.96%	17.73%	—	10.47%
Jun 2024	69.84%	1.42%	18.93%	—	9.82%
Sep 2024	69.84%	1.94%	18.3%	—	9.94%
Dec 2024	69.84%	2.53%	19%	—	8.63%
Mar 2025	69.84%	2.69%	20.1%	—	7.37%
Jun 2025	69.84%	1.39%	19.43%	—	9.34%
Sep 2025	69.84%	1.56%	19.04%	—	9.57%
Dec 2025	69.84%	1.17%	19.38%	—	9.61%
Mar 2026	69.84%	0.87%	20.24%	—	9.04%
Jun 2026	69.84%	0.8%	20.75%	—	8.62%
Sep 2026	74.45%	0.93%	17.44%	—	7.17%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	85	354	3211	506	4156	1697	282	125	2053	4156
Mar 2016	89	82	3214	577	3963	1540	280	125	2017	3963
Mar 2017	89	-432	3106	595	3358	1402	288	125	1543	3358
Mar 2018	89	-763	3202	683	3211	1291	272	125	1523	3211
Mar 2019	89	-844	3230	518	2993	1161	278	0	1553	2993
Mar 2020	41	757	566	86	1450	858	26	0	566	1450
Mar 2021	41	641	453	90	1224	670	7	15	531	1224
Mar 2022	41	637	268	148	1094	584	10	49	452	1094
Mar 2023	41	691	331	160	1223	573	46	50	554	1223
Mar 2024	51	1168	135	199	1552	616	24	69	842	1552
Mar 2025	15	1551	154	366	2086	688	44	80	1274	2086
Mar 2026	15	1587	129	367	2098	671	168	88	1171	2098

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	-370	1334	-597	367
Mar 2016	211	-1	-287	-76
Mar 2017	402	-176	-465	-239
Mar 2018	6	-28	33	11
Mar 2019	15	45	0	60
Mar 2020	80	167	-250	-3
Mar 2021	24	67	-165	-73
Mar 2022	90	113	-217	-14
Mar 2023	13	-27	31	18
Mar 2024	131	-316	167	-18
Mar 2025	64	-51	3	15
Mar 2026	142	-116	-41	-15

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	61	156	101	82	88	50	107	105	116	84	92	113
Inventory Days	113	183	196	204	219	257	240	201	217	199	187	161
Days Payable	138	307	410	361	354	110	109	140	130	135	116	119
Cash Conversion Cycle	36	32	-113	-74	-47	197	237	165	204	148	163	154
Working Capital Days	-32	-127	-504	-901	-1,159	197	330	121	79	140	112	124
ROCE %	1%	2%	-3%	-3%	-5%	-4%	-4%	-2%	5%	9%	10%	3%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of ORCHID PHARMA LIMITED (ORCHPHARMA)?

The reported market capitalisation for ORCHID PHARMA LIMITED (ORCHPHARMA) is ₹5,457Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of ORCHPHARMA?

The current price shown for ORCHID PHARMA LIMITED (ORCHPHARMA) on Fincrux is ₹911 with a 52-week high/low of ₹1,144/471.

What is the P/E ratio of ORCHID PHARMA LIMITED (ORCHPHARMA)?

The stock P/E for ORCHID PHARMA LIMITED (ORCHPHARMA) is 113 on Fincrux, with ROE at 2.98% and ROCE at 3.28%.

What were ORCHPHARMA latest quarterly results?

For Jun 2026, ORCHID PHARMA LIMITED (ORCHPHARMA) reported sales ₹304 Cr and net profit ₹12 Cr (figures in ₹ crore unless noted).

What are ORCHPHARMA annual sales and net profit?

For TTM, ORCHID PHARMA LIMITED (ORCHPHARMA) shows sales of ₹1,073 Cr and net profit of ₹41 Cr on the Fincrux profit & loss statement.

Who owns ORCHID PHARMA LIMITED (ORCHPHARMA)?

Latest shareholding for ORCHID PHARMA LIMITED (ORCHPHARMA) on Fincrux: Promoters 74.45% (Sep 2026), FIIs 0.93% (Sep 2026), DIIs 17.44% (Sep 2026), Public 7.17% (Sep 2026), No. of Shareholders 33,790% (Sep 2026).

Where can I find ORCHID PHARMA LIMITED (ORCHPHARMA) financials?

ORCHID PHARMA LIMITED (ORCHPHARMA) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show ORCHPHARMA balance sheet and cash flow?

Yes. The ORCHID PHARMA LIMITED (ORCHPHARMA) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 10:26